NCT02253251View on ClinicalTrials.gov

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

RecruitingOBSERVATIONAL
Enrollment

15,000

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2030

Study Completion Date

September 30, 2035

Conditions
Cancer
Interventions
GENETIC

KRAS-variant and microRNA binding site mutation testing

Participant in these studies will be tested for the KRAS-variant

Trial Locations (1)

90025

RECRUITING

MiraKind, Los Angeles

Sponsors

Lead Sponsor

MiraKind
All Listed Sponsors
lead

MiraKind

OTHER

NCT02253251 - Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment | Biotech Hunter | Biotech Hunter